


POSITION STATEMENT ON INTRODUCTION OF WHOLE GENOME SEQUENCING FOR HAEMATO-ONCOLOGY**FEBRUARY 2020**

Whole genome sequencing (WGS) will soon be available in England as an NHS commissioned test for patients with both inherited and acquired conditions. Within haematological malignancy, all patients presenting with acute leukaemia and all paediatric patients (any presentation) will be eligible for WGS.

WGS will be performed alongside standard of care tests. In addition to the tumour sample, a source of germline DNA and a patient 'Record of Discussion' form need to be available for WGS to proceed. The preferred source of germline DNA in haematological neoplasia is saliva collected once blasts have cleared from the peripheral blood. As stipulated by NHSE, acute leukaemia diagnosis will need to be confirmed by an HMDS in order to proceed with WGS, with results integrated by an HMDS into the final diagnosis, alongside those from standard of care testing. Detailed instructions regarding patient and sample eligibility, and the process for accessing WGS, will be distributed to all referring centres before the WGS service is launched.

The phased clinical launch of the WGS service will begin no earlier than mid-May 2020, with **full implementation planned from July 2020**. These dates are subject to change.

Further information about WGS will be disseminated to service users once a firm date for launch of the service has been agreed.



Joanne Mason
Consultant Clinical Scientist
Head of Haemato-oncology, WMRGL



Professor Mike Griffiths
Director, WMRGL
Scientific Director, WMOWGLH



Fiona Clark
Consultant Haematologist
MIRHO Clinical Lead